2cureX announced a new go-to-market strategy to strengthen its commercial activities in the North of Europe. 2cureX has signed a distribution agreement with Algol Diagnostics Oy, Under the terms of the collaboration, Algol Diagnostics will promote IndiTreat® to oncology professionals, sign supply agreements with hospitals and manage the sample logistics between the hospitals and 2cureX labs in Copenhagen. Commercial operations in Sweden, Norway and Germany will be conducted directly by 2cureX, who is already in charge of the commercialization in Denmark.

The company expects that the direct interaction with customers in Sweden and Norway will result in a faster rollout of the IndiTreat® tests. The activities in Germany will initially aim at engaging local Key Opinion Leaders through the IGNITE program to support the inclusion of the test in the hospital guidelines.